Evidence map›Paper›PMID 41692929›Full record

ReviewDiscover nano2026

The application of metal nanomaterials in cancer diagnosis and treatment.

Kai Kang, Yahong Wu, Kang Liu, Ze Wang, Tong Sha

Abstract readReview
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kai Kang *Department of Oral Emergency and Mucosal Medicine, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Yahong Wu *Department of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China.
Kang LiuDepartment of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China. kangliu22@mails.jlu.edu.cn.
Ze WangState Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, People's Republic of China.
Tong ShaDepartment of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun, 130021, People's Republic of China. shatong22@mails.jlu.edu.cn.

Funding

Postdoctoral Fellowship Program of CPSF GZB20250444
6 · The paper itself

Abstract

Cancer remains one of the most serious life-threatening diseases and a major threat to public health systems worldwide. Current diagnostic and therapeutic approaches face persistent hurdles, including toxicity resulting from the distribution of non-specific systemic anti-tumor agents, inadequate drug concentrations at tumor sites, and difficulties in achieving precise tumor localization alongside integrated diagnosis and therapy. Therefore, there is an urgent need for more efficient treatment strategies and accurate diagnostic methods with minimal side effects. Metal nanomaterials (particularly those based on gold, manganese, silver, copper, and palladium), when used individually or in combination, have emerged as promising agents in bioengineered cancer therapy. These metal nanomaterials have gained significant attention in the field of biological imaging, cancer cell targeting, photothermal therapy, photodynamic therapy, chemodynamic therapy and immunotherapy. Moreover, metal nanomaterials-mediated drug delivery systems can achieve the ability to specifically initiate and control drug release in tumor regions by responding to specific exogenous stimuli (including temperature, enzymes, light stimulation, magnetic fields, and ultrasound stimulation) or endogenous stimuli of the TME (such as pH value, redox environment, or interstitial pressure), which is expected to further improve the therapeutic effect. In this review, we focus on the application of metal nanomaterials in cancer diagnosis and treatment, and discuss the promising strategies for effective treatment, with the aim of providing new ideas for the application of metal nanomaterials in clinical tumor treatment.

Indexed as

Cancer treatment and diagnosisControlled releaseMetal nanomaterialsSynergistic therapyTargeted delivery

Identifiers

PMID41692929
PMCPMC12907292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.